Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilars On The Horizon: How Much Will FDA Look To The East?

This article was originally published in The Pink Sheet Daily

Executive Summary

Europe's pathway for follow-on biologics has selling points for both brand and generic firms, but FDA will chart its own course - even as it mulls accepting European data.
Advertisement

Related Content

Practice Makes Good: FDA, EMA Focus On CROs As GCP Info Sharing Improves
Practice Makes Good: FDA, EMA Focus On CROs As GCP Info Sharing Improves
Biosimilar Guidance: Brands Try Again For A Pre-Approval Requirement
Biosimilar Guidance: Brands Try Again For A Pre-Approval Requirement
Sanders Bill Would Allow Biosimilar “Pay-For-Data” System
Could Innovators Help Biosimilar Manufacturers?
Could Innovators Help Biosimilar Manufacturers?
FDA Signals Interest In Requiring Unique Biosimilar Names
Biosimilar Threat Looms For J&J, Amgen And Others, Decision Resources Forecasts
Biosimilar Threat Looms For J&J, Amgen And Others, Decision Resources Forecasts

Topics

Advertisement
UsernamePublicRestriction

Register

PS071415

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel